All In Biotech

Drug Trial Radar · NCT02964260

RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma

Randomized Controlled Trial of Transarterial Embolization Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

410

Planned (sponsor's estimate)

Start

May 2016

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Third Affiliated Hospital, Sun Yat-Sen University; Sixth Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial People's Hospital
First posted
Nov 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study intends to evaluate the efficacy and safety of Transarterial embolization (TAE) simultaneously combined with thermal ablation for large hepatocellular carcinoma (HCC). Half participants will receive TAE simultaneously combined with thermal ablation and the other half receive TACE sequentially combined with thermal ablation, which is a conventional treatment for HCC patients.

Conditions

  • Hepatocellular Carcinoma, Adult

Interventions

  • Chemotherapy drugDrug

    Doxorubicin/Platinum agents

  • Embolic agentsDrug

    Lipiodol/Gelatin sponge/PVA/Blank microspheres

  • SimultaneouslyProcedure

    1-3 days

  • SequentiallyProcedure

    1 month

  • AblationDevice

    Radiofrequency ablation/Microwave ablation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.